Impact of Different Oseltamivir Regimens on Treating Influenza A Virus Infection and Resistance Emergence: Insights from a Modelling Study

PLoS Computational Biology

Volumn 10, Issue 4, 2014, Pages

  Canini, Laetitia ^a,b,c   Conway, Jessica M ^c   Perelson, Alan S ^c   Carrat, Fabrice ^a,b,d  

^a INSTITUT PIERRE LOUIS D EPIDÉMIOLOGIE ET DE SANTÉ PUBLIQUE   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c LOS ALAMOS NATIONAL LABORATORY   (United States)

^d HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COMBINING MODEL; DRUG-RESISTANT VIRUS; INCUBATION PERIODS; INFLUENZA A VIRUS; INITIATION TIME; MODELLING STUDIES; OSELTAMIVIR; SELECTIVE PRESSURE; VIRUS INFECTION; VIRUS RESISTANCE;

VIRUSES;

OSELTAMIVIR; ANTIVIRUS AGENT;

ANTIVIRAL RESISTANCE; ARTICLE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; INFECTION PREVENTION; INFLUENZA A; INFLUENZA VIRUS A; TREATMENT DURATION; VIRUS REPLICATION; VIRUS SHEDDING; DRUG EFFECTS; HUMAN; INFLUENZA, HUMAN; ISOLATION AND PURIFICATION; THEORETICAL MODEL; VIROLOGY;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HUMANS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; MODELS, THEORETICAL; OSELTAMIVIR;

EID: 84901355597     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1003568     Document Type: Article

References (55)

1. Burch J, Corbett M, Stock C, Nicholson K, Elliot AJ, et al. (2009) Prescription of anti-influenza drugs for healthy adults: a systematic review and meta-analysis. Lancet Infect Dis 9: 537-545.
2. Hayden FG, Osterhaus AD, Treanor JJ, Fleming DM, Aoki FY, et al. (1997) Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med 337: 874-880.
3. Hayden FG, Treanor JJ, Fritz RS, Lobo M, Betts RF, et al. (1999) Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 282: 1240-1246.
4. Monto AS, (2003) The role of antivirals in the control of influenza. Vaccine 21: 1796-1800.
5. NICE (2009) Amantadine, oseltamivir and zanamivir for the treatment, Review of NICE technology appraisal guidance 58. London: National Institute for Clinical Excellence.
6. World Health Organization (2004) WHO guidelines on the use of vaccines and antivirals during influenza pandemics. Geneva, Switzerland: [Online.] http://www.who.int/csr/resources/publications/influenza/11_29_01_A.pdf.
7. Gubareva LV, Kaiser L, Hayden FG, (2000) Influenza virus neuraminidase inhibitors. Lancet 355: 827-835.
8. Patel A, Gorman SE, (2009) Stockpiling antiviral drugs for the next influenza pandemic. Clin Pharmacol Ther 86: 241-243.
9. Jefferson T, Jones M, Doshi P, Del Mar C, (2009) Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. BMJ 339: b5106.
10. Reece PA, (2007) Neuraminidase inhibitor resistance in influenza viruses. J Med Virol 79: 1577-1586.
11. Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten RJ, Xu X, et al. (2008) Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 52: 3284-3292.
12. World Health Organization (2009) Pandemic (H1N1) 2009- update 67. [Online.] http://www.who.int/csr/don/2009_09_25/en/index.html.
13. Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, et al. (2004) Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364: 759-765.
14. Whitley RJ, Hayden FG, Reisinger KS, Young N, Dutkowski R, et al. (2001) Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 20: 127-133.
15. Chen LF, Dailey NJ, Rao AK, Fleischauer AT, Greenwald I, et al. (2010) Cluster of oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infections on a hospital ward among immunocompromised patients-North Carolina, 2009. J Infect Dis 203: 838-846.
16. Renaud C, Boudreault AA, Kuypers J, Lofy KH, Corey L, et al. (2011) H275Y mutant pandemic (H1N1) 2009 virus in immunocompromised patients. Emerg Infect Dis 17: 653-660 quiz 765.
17. World Health Organization (2010) Update on oseltamivir resistant pandemic A (H1N1) 2009 influenza virus: January 2010. Weekly Epidemiological Record 85: 37-40.
18. Canini L, Carrat F, (2011) Population modeling of influenza A/H1N1 virus kinetics and symptom dynamics. J Virol 85: 2764-2770.
19. Rayner CR, Chanu P, Gieschke R, Boak LM, Jonsson EN, (2008) Population pharmacokinetics of oseltamivir when coadministered with probenecid. J Clin Pharmacol 48: 935-947.
20. Wattanagoon Y, Stepniewska K, Lindegardh N, Pukrittayakamee S, Silachamroon U, et al. (2009) Pharmacokinetics of high-dose oseltamivir in healthy volunteers. Antimicrob Agents Chemother 53: 945-952.
21. (2008) Tamiflu (R) (oseltamivir phosphate) capsules and for oral suspension. Package Insert. Foster City, California: Roche Laboratories Inc Gilead Sciences Inc.
22. Baccam P, Beauchemin C, Macken CA, Hayden FG, Perelson AS, (2006) Kinetics of influenza A virus infection in humans. J Virol 80: 7590-7599.
23. Handel A, Longini IM Jr, Antia R, (2010) Towards a quantitative understanding of the within-host dynamics of influenza A infections. J R Soc Interface 7: 35-47.
24. Govorkova EA, Ilyushina NA, Marathe BM, McClaren JL, Webster RG, (2010) Competitive fitness of oseltamivir-sensitive and-resistant highly pathogenic H5N1 influenza viruses in a ferret model. J Virol 84: 8042-8050.
25. Wu NC, Young AP, Dandekar S, Wijersuriya H, Al-Mawsawi LQ, et al. (2013) Systematic identification of H274Y compensatory mutations in influenza A virus neuraminidase by high-throughput screening. J Virol 87: 1193-1199.
26. Gubareva LV, Webster RG, Hayden FG, (2001) Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrob Agents Chemother 45: 3403-3408.
27. Alfonsi A, Cances E, Turinici G, Di Ventura B, Huisinga W (2004) Exact simulation of hybrid stochastic and deterministic models for biochemical systems. INRIA Report No. 5435.
28. Handel A, Longini IM Jr, Antia R, (2007) Neuraminidase inhibitor resistance in influenza: assessing the danger of its generation and spread. PLoS Comput Biol 3: e240.
29. Hayden FG, (2001) Perspectives on antiviral use during pandemic influenza. Philos Trans R Soc Lond B Biol Sci 356: 1877-1884.
30. Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, et al. (2000) Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 283: 1016-1024.
31. World Health Organization (2010) WHO Guidelines for Pharmacological Management of Pandemic Influenza A(H1N1) 2009 and other Influenza Viruses- Part I Recommendations. [online] http://www.who.int/csr/resources/publications/swineflu/h1n1_guidelines_pharmaceutical_mngt.pdf.
32. Cowling BJ, Chan KH, Fang VJ, Lau LL, So HC, et al. (2010) Comparative epidemiology of pandemic and seasonal influenza A in households. N Engl J Med 362: 2175-2184.
33. Beauchemin C, Samuel J, Tuszynski J, (2005) A simple cellular automaton model for influenza A viral infections. J Theor Biol 232: 223-234.
34. Bocharov GA, Romanyukha AA, (1994) Mathematical model of antiviral immune response. III. Influenza A virus infection. J Theor Biol 167: 323-360.
35. Hancioglu B, Swigon D, Clermont G, (2007) A dynamical model of human immune response to influenza A virus infection. J Theor Biol 246: 70-86.
36. Lee HY, Topham DJ, Park SY, Hollenbaugh J, Treanor J, et al. (2009) Simulation and prediction of the adaptive immune response to influenza A virus infection. J Virol 83: 7151-7165.
37. Miao H, Hollenbaugh JA, Zand MS, Holden-Wiltse J, Mosmann TR, et al. (2010) Quantifying the early immune response and adaptive immune response kinetics in mice infected with influenza A virus. J Virol 84: 6687-6698.
38. Harris LA, Clancy P, (2006) A "partitioned leaping" approach for multiscale modeling of chemical reaction dynamics. J Chem Phys 125: 144107.
39. Abed Y, Pizzorno A, Bouhy X, Rhéaume C, Boivin G, (2014) Impact of Potential Permissive Neuraminidase Mutations on Viral Fitness of the H275Y Oseltamivir-Resistant Influenza A (H1N1) pdm09 Virus In Vitro, in Mice and in Ferrets. J Virol 88: 1652-1658.
40. Abed Y, Pizzorno A, Bouhy X, Boivin G, (2011) Role of permissive neuraminidase mutations in influenza A/Brisbane/59/2007-like (H1N1) viruses. PLoS Pathog 7: e1002431.
41. Guarnaccia T, Carolan LA, Maurer-Stroh S, Lee RT, Job E, et al. (2013) Antigenic Drift of the Pandemic 2009 A (H1N1) Influenza Virus in a Ferret Model. PLoS Pathog 9: e1003354.
42. Aoki FY, Macleod MD, Paggiaro P, Carewicz O, El Sawy A, et al. (2003) Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 51: 123-129.
43. Louie JK, Yang S, Acosta M, Yen C, Samuel MC, et al. (2012) Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. Clin Infect Dis 55: 1198-1204.
44. Muthuri SG, Myles PR, Venkatesan S, Leonardi-Bee J, Nguyen-Van-Tam JS, (2013) Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A (H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients. J Infect Dis 207: 553-563.
45. Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, et al. (2000) Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 355: 1845-1850.
46. Monto AS, McKimm-Breschkin JL, Macken C, Hampson AW, Hay A, et al. (2006) Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother 50: 2395-2402.
47. Gubareva LV, Kaiser L, Matrosovich MN, Soo-Hoo Y, Hayden FG, (2001) Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J Infect Dis 183: 523-531.
48. Fry AM, Goswami D, Nahar K, Sharmin AT, Rahman M, et al. (2014) Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial. Lancet Infect Dis 14: 109-118.
49. Conway JM, Konrad BP, Coombs D, (2013) Stochastic Analysis of Pre-and Postexposure Prophylaxis against HIV Infection. SIAM J Appl Math 73: 904-928.
50. Pearson JE, Krapivsky P, Perelson AS, (2011) Stochastic theory of early viral infection: Continuous versus burst production of virions. PLoS Comput Biol 7: e1001058.
51. Maltezou HC, Drakoulis N, Siahanidou T, Karalis V, Zervaki E, et al. (2011) Safety and Pharmacokinetics of Oseltamivir for Prophylaxis of Neonates Exposed to Influenza H1N1. Pediatr Infect Dis J 31: 527-9 doi:10.1097/INF.0b013e3182472f28.
52. Oo C, Hill G, Dorr A, Liu B, Boellner S, et al. (2003) Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years. Eur J Clin Pharmacol 59: 411-415.
53. Lau LL, Ip DK, Nishiura H, Fang VJ, Chan K-H, et al. (2013) Heterogeneity in viral shedding among individuals with medically attended influenza A virus infection. J Infect Dis 207: 1281-1285.
54. Whitley RJ, Boucher CA, Lina B, Nguyen-Van-Tam JS, Osterhaus A, et al. (2013) Global assessment of resistance to neuraminidase inhibitors, 2008-2011: the Influenza Resistance Information Study (IRIS). Clin Infect Dis 56: 1197-1205.
55. Ison MG, (2014) Optimum timing of oseltamivir: lessons from Bangladesh. Lancet Infect Dis 14: 88-89.